9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease

      research-article
      a , a , a , a , c , d , a , a , a , c , h , b , c , a , c , h , a , c , a , b , a , e , f , g , h , i , m , j , k , l , c , a , c , a , c , b , c , a , a , c , a , b , c , *
      Neurobiology of disease
      Phosphorylated tau, ADAD, White matter, PCA, CSF

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Hyperphosphorylation of tau leads to conformational changes that destabilize microtubules and hinder axonal transport in Alzheimer’s disease (AD). However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s).

          Methods:

          In autosomal dominant AD (ADAD) mutation carriers (MC) and non-carriers (NC) we compared cerebrospinal fluid (CSF) phosphorylation at tau sites (pT217, pT181, pS202, and pT205) and total tau with WM measures, as derived from diffusion tensor imaging (DTI), and cognition. A WM composite metric, derived from a principal component analysis, was used to identify spatial decline seen in ADAD.

          Results:

          The WM composite explained over 70% of the variance in MC. WM regions that strongly contributed to the spatial topography were located in callosal and cingulate regions. Loss of integrity within the WM composite was strongly associated with AD progression in MC as defined by the estimated years to onset (EYO) and cognitive decline. A linear regression demonstrated that amyloid, gray matter atrophy and phosphorylation at CSF tau site pT205 each uniquely explained a reduction in the WM composite within MC that was independent of vascular changes (white matter hyperintensities), and age. Hyperphosphorylation of CSF tau at other sites and total tau did not significantly predict WM composite loss.

          Conclusions:

          We identified a site-specific relationship between CSF phosphorylated tau and WM decline within MC. The presence of both amyloid deposition and Tau phosphorylation at pT205 were associated with WM composite loss. These findings highlight a primary AD-specific mechanism for WM dysfunction that is tightly coupled to symptom manifestation and cognitive decline.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: not found
          • Article: not found

          "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The Clinical Dementia Rating (CDR): current version and scoring rules.

            J Morris (1993)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data.

              There has been much recent interest in using magnetic resonance diffusion imaging to provide information about anatomical connectivity in the brain, by measuring the anisotropic diffusion of water in white matter tracts. One of the measures most commonly derived from diffusion data is fractional anisotropy (FA), which quantifies how strongly directional the local tract structure is. Many imaging studies are starting to use FA images in voxelwise statistical analyses, in order to localise brain changes related to development, degeneration and disease. However, optimal analysis is compromised by the use of standard registration algorithms; there has not to date been a satisfactory solution to the question of how to align FA images from multiple subjects in a way that allows for valid conclusions to be drawn from the subsequent voxelwise analysis. Furthermore, the arbitrariness of the choice of spatial smoothing extent has not yet been resolved. In this paper, we present a new method that aims to solve these issues via (a) carefully tuned non-linear registration, followed by (b) projection onto an alignment-invariant tract representation (the "mean FA skeleton"). We refer to this new approach as Tract-Based Spatial Statistics (TBSS). TBSS aims to improve the sensitivity, objectivity and interpretability of analysis of multi-subject diffusion imaging studies. We describe TBSS in detail and present example TBSS results from several diffusion imaging studies.
                Bookmark

                Author and article information

                Journal
                9500169
                20475
                Neurobiol Dis
                Neurobiol Dis
                Neurobiology of disease
                0969-9961
                1095-953X
                20 November 2022
                15 June 2022
                28 March 2022
                27 November 2022
                : 168
                : 105714
                Affiliations
                [a ]Department of Neurology, Washington University, St. Louis, MO 63110, USA
                [b ]Department of Radiology, Washington University, St. Louis, MO 63110, USA
                [c ]Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63110, USA
                [d ]Department of Psychological & Brain Sciences, Washington University, St. Louis, MO 63110, USA
                [e ]Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA
                [f ]Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
                [g ]Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA
                [h ]Osaka City University School of Medicine Asahimachi, Abenoku, Osaka 545-8585, Japan
                [i ]German Center for Neurodegenerative Disease (DZNE) Munich, Munich, Germany
                [j ]School of Medicine, Universidad de Buenos Aires, Viamonte 430, C1053 CABA, Argentina
                [k ]Neuroscience Research Australia, Sydney, NSW, Australia
                [l ]Hope Center for Neurological Disorders, Washington University, St. Louis, MO 63100, USA
                [m ]Department of Neurology, Columbia University, New York, NY 100310, USA
                Author notes
                [1]

                Contributed equally for first authorship.

                Author contribution

                Jeremy F. Strain: Reports no disclosures.

                Nicolas Barthelemy: Could receive part of the profits from any sales of these phosphorylation site tests by C2N, which is in the process of licensing or has licensed some IP from the University.

                Kanta Horie: Reports no disclosures.

                Brian A. Gordon: Involved on a clinical trial sponsored by Avid.

                Collin Kilgore: Reports no disclosures.

                Andrew Aschenbrenner: Reports no disclosures.

                Carlos Cruchaga: Reports no disclosures.

                Chengjie Xiong: Reports no disclosures.

                Nelly Joseph-Mathurin: Reports no disclosures.

                Jason Hassenstab: Reports no disclosures.

                Anne M. Fagan: Reports no disclosures.

                Yan Li: Reports no disclosures.

                Celeste M. Karch: Reports no disclosures.

                Richard Perrin: Reports no disclosures.

                Sarah B. Berman: Reports no disclosures.

                Jasmeer P. Chhatwal: Reports no disclosures.

                Neill R. Graff-Radford: Research support includes AbbVie, Novartis, Biogen and Lilly.

                Hiroshi Mori: Reports no disclosures.

                Johannes Levin: Reports no disclosures.

                James Noble: Reports no disclosures.

                Ricardo Allegri: Reports no disclosures.

                Peter R. Schofield: Reports no disclosures.

                Daniel S. Marcus Reports no disclosures.

                David M. Holtzman: Cofounded and is on the scientific advisory board of C2N diagnostics, LLC. Is on the scientific advisory board of Denali and consults for Genetech and AbbVie. Could receive part of the profits from any sales of these phosphorylation site tests by C2N, which is in the process of licensing or has licensed some IP from the University.

                John C. Morris: He is currently participating in clinical trials of antidementia drugs developed by Eli Lilly and Company, Biogen and Janssen. Dr. Morris serves as a consultant for Lilly USA. Research support from Eli Lilly/Avid Radiopharmaceuticals.

                Tammie L.S. Benzinger: Involved in a clinical trial sponsored by Avid.

                Eric M. McDade: Research support: NIA, Eli Lilly, Roche, Janssen, GHR Foundation; Advisory Board: Eli Lilly; DSMB: Eli Lilly. Could receive part of the profits from any sales of these phosphorylation site tests by C2N, which is in the process of licensing or has licensed some IP from the University.

                Randall J. Bateman: He is on the scientific advisory board for C2N Diagnostics. Research support from Abbvie, Biogen, Eisai, Eli Lilly, and Co/Avid Radiopharmaceuticals, Roche, Janssen, and United Neuroscience. Could receive part of the profits from any sales of these phosphorylation site tests by C2N, which is in the process of licensing or has licensed some IP from the University.

                Beau M. Ances: Involved in a clinical trial sponsored by Avid.

                [* ]Corresponding author at: Washington University in St. Louis, Box 8111, 660 South Euclid Ave, Saint Louis, MO 63110, USA, bances@ 123456wustl.edu (B.M. Ances).
                Article
                NIHMS1846968
                10.1016/j.nbd.2022.105714
                9701560
                35358703
                1be61878-a089-4912-aa92-58262f6fb1be

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                Neurosciences
                phosphorylated tau,adad,white matter,pca,csf
                Neurosciences
                phosphorylated tau, adad, white matter, pca, csf

                Comments

                Comment on this article